tiprankstipranks
Advertisement
Advertisement
Definium Therapeutics announces results from Phase 3 study of DT120
PremiumThe FlyDefinium Therapeutics announces results from Phase 3 study of DT120
12d ago
Definium Therapeutics price target raised to $70 from $60 at Oppenheimer
Premium
The Fly
Definium Therapeutics price target raised to $70 from $60 at Oppenheimer
12d ago
Definium Therapeutics price target raised to $66 from $50 at Needham
Premium
The Fly
Definium Therapeutics price target raised to $66 from $50 at Needham
12d ago
Definium Therapeutics price target raised to $66 from $57 at RBC Capital
PremiumThe FlyDefinium Therapeutics price target raised to $66 from $57 at RBC Capital
12d ago
Psychedelic: Definium’s LSD-based pill meets endpoints in GAD study
Premium
The Fly
Psychedelic: Definium’s LSD-based pill meets endpoints in GAD study
12d ago
Definium Therapeutics price target raised to $55 from $50 at Maxim
Premium
The Fly
Definium Therapeutics price target raised to $55 from $50 at Maxim
12d ago
Definium Therapeutics Posts Strong Phase 3 Data and Capital Raise to Fund Psychedelic Pipeline
PremiumCompany AnnouncementsDefinium Therapeutics Posts Strong Phase 3 Data and Capital Raise to Fund Psychedelic Pipeline
22d ago
Definium Therapeutics reports Q2 EPS ($1.44), consensus (53c)
Premium
The Fly
Definium Therapeutics reports Q2 EPS ($1.44), consensus (53c)
22d ago
Definium Therapeutics, Inc. options imply 14.8% move in share price post-earnings
Premium
The Fly
Definium Therapeutics, Inc. options imply 14.8% move in share price post-earnings
22d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100